An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis - Join Clinical Trial NCTNCT05809531
How to Join This Clinical Trial - NCTNCT05809531
Learn how to participate in this PHASE3 trial studying an investigational therapy for C3G, IC-MPGN, C3 Glomerulopathy, C3 Glomerulonephritis, Complement 3 Glomerulopathy, Complement 3 Glomerulopathy (C3G), Complement 3 Glomerulonephritis, Dense Deposit Disease, DDD, Membranoproliferative Glomerulonephritis, Membranoproliferative Glomerulonephritis (MPGN), Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN). Current status: ACTIVE_NOT_RECRUITING.
Am I Eligible for This Clinical Trial?
This clinical research study is looking for participants with C3G, IC-MPGN, C3 Glomerulopathy, C3 Glomerulonephritis, Complement 3 Glomerulopathy, Complement 3 Glomerulopathy (C3G), Complement 3 Glomerulonephritis, Dense Deposit Disease, DDD, Membranoproliferative Glomerulonephritis, Membranoproliferative Glomerulonephritis (MPGN), Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN). Eligibility requirements include specific age ranges, health status, and medical history. Contact the study team to learn if you qualify.
- Condition Being Studied
- C3G, IC-MPGN, C3 Glomerulopathy, C3 Glomerulonephritis, Complement 3 Glomerulopathy, Complement 3 Glomerulopathy (C3G), Complement 3 Glomerulonephritis, Dense Deposit Disease, DDD, Membranoproliferative Glomerulonephritis, Membranoproliferative Glomerulonephritis (MPGN), Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)
- Treatment Being Tested
- Investigational treatment
- Study Phase
- PHASE3 - Large-scale efficacy study
- Enrollment Status
- ACTIVE_NOT_RECRUITING
- Study Identifier
- NCTNCT05809531 - ClinicalTrials.gov Identifier
- Sponsored By
- Study sponsor
What to Expect as a Participant
Participating in this clinical trial involves:
- Initial screening to determine eligibility
- Regular study visits and health assessments
- Receiving the study treatment or placebo
- Medical monitoring and follow-up care
- Contributing to medical research that may help others
- Potential access to new treatments before they're widely available
Clinical Trial Benefits and Compensation
Participants in this clinical research study may receive:
- Close medical monitoring by healthcare professionals
- Access to potential new treatments
- Compensation for time and travel (varies by study)
- No-cost study-related medical care
- The opportunity to help advance medical knowledge
Where Is This Clinical Trial Located?
This study is enrolling participants at 47 locations. Find a study site near you:
Clinical Research Site
Los Angeles, California 90022 - United States
Status: Contact for availability
Clinical Research Site
Aurora, Colorado 80045 - United States
Status: Contact for availability
Clinical Research Site
Gainesville, Florida 32610 - United States
Status: Contact for availability
Clinical Research Site
Atlanta, Georgia 30322 - United States
Status: Contact for availability
Clinical Research Site
Iowa City, Iowa 52242 - United States
Status: Contact for availability
Clinical Research Site
Ann Arbor, Michigan 48109 - United States
Status: Contact for availability
Clinical Research Site
Hackensack, New Jersey 07601 - United States
Status: Contact for availability
Clinical Research Site
Hyde Park, New York 11040 - United States
Status: Contact for availability
Clinical Research Site
New York, New York 10032 - United States
Status: Contact for availability
Clinical Research Site
Portland, Oregon 97239 - United States
Status: Contact for availability
And 37 more locations available. Contact us to find the nearest participating site.
How to Enroll in This Study
To learn more about participating in this PHASE3 clinical trial for C3G, IC-MPGN, C3 Glomerulopathy, C3 Glomerulonephritis, Complement 3 Glomerulopathy, Complement 3 Glomerulopathy (C3G), Complement 3 Glomerulonephritis, Dense Deposit Disease, DDD, Membranoproliferative Glomerulonephritis, Membranoproliferative Glomerulonephritis (MPGN), Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN):
- Review the eligibility criteria with your healthcare provider
- Contact the study team for a pre-screening interview
- Schedule an in-person screening visit if eligible
- Review and sign the informed consent form
- Begin participation in the clinical trial
Why Choose Quri.ai as Your Clinical Trial Matching Service
Quri.ai is a free clinical trial matching service that helps patients connect with research sites. We make it easier to:
- Find clinical trials that match your condition
- Get matched to the right study location near you
- Connect directly with study coordinators
- Understand if you qualify with simplified eligibility screening
- Navigate the enrollment process with personalized support
- Access new treatments through clinical research participation